EUVIMEDEUVIMED entdecken
Crossref

Percutaneous microwave ablation of cT1b renal cell carcinoma: safety and oncologic efficacy in a large, single-center elderly and comorbid cohort

Shane A Wells, Daniel Shapiro, Tudor Borza, Glenn Allen, J Louis Hinshaw, Timothy J Ziemlewicz, Christopher L Brace, Alice M Semerjian, E Jason Abel

Abdominal Radiology · 2025

DOI: 10.1007/s00261-024-04794-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Abdominal Radiology, 2025. Verfasst von Shane A Wells und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-5030, USA. shanewel@med.umich.edu. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Microwaves, Catheter Ablation. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate safety and oncologic efficacy of percutaneous microwave ablation (MWA) for treating clinically localized T1b (cT1b) renal cell carcinoma (RCC). METHODS: This single-center retrospective study was performed under a waiver of informed consent. Seventy-four consecutive patients (49M/25F) with 76 cT1b RCC (median tumor diameter 4.5 cm) were treated with percutaneous MWA between 5/2012 and 8/2020. Patients were stratified into two groups by technique, depending on whether antennas were repositioned for additional ablation or not. Primary efficacy, complications, and local tumor progression (LTP) were compared using the Wilcoxon rank sum and Fisher's exact tests. The Kaplan Meier method was used for survival analysis. RESULTS: Patients were elderly (median age 69.5), obese (median BMI 34.5), and comorbid (Charlson Comorbidity Index = 4). Most tumors were low-grade (grade 1-2) (67/89, 88%) and clear cell RCC was the most common histology (62/76, 82%). A median of three MWA antennas were powered at 65 W for 7 min for treatment. Renal masses were larger (4.6 vs 4.5 cm, p = 0.01) and procedure times longer (100 min vs 80.5 min, p = 0.04) for the antenna reposition cohort (n = 34, 45%). Primary efficacy and high-grade complication rates were 93% and 8%, respectively. The local tumor progression rate (LTP), at a median follow-up was 28.2 months, was 16%. Primary efficacy, low and high-grade complications, change in estimated glomerular filtration rate and LTP were similar between cohorts (p = 0.20-0.55). CONCLUSION: Percutaneous MWA for cT1b RCC is safe in elderly and comorbid patients with acceptable oncologic efficacy. Repeat ablation is well-tolerated and can improve oncologic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsMicrowavesCatheter AblationAblation TechniquesHumansFemaleMaleAgedRetrospective StudiesTreatment OutcomeMiddle AgedAged, 80 and overComorbidityNeoplasm Staging

Stichwörter der Autor:innen

AblationEmbolizationMWAMicrowaveRCCRenal cell carcinomaT1b

Autor:innen und Institutionen

  • Department of Radiology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-5030, USA. shanewel@med.umich.edu.
  • Department of Urology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-5030, USA. shanewel@med.umich.edu.
  • Department of Urology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
  • Department of Urology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-5030, USA.
  • Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
  • Departments of Engineering and Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.

Zitieren

APA

Wells, S. A., Shapiro, D., Borza, T., Allen, G., Hinshaw, J. L., Ziemlewicz, T. J., Brace, C. L., Semerjian, A. M., & Abel, E. J. (2025). Percutaneous microwave ablation of cT1b renal cell carcinoma: safety and oncologic efficacy in a large, single-center elderly and comorbid cohort. Abdominal Radiology. https://doi.org/10.1007/s00261-024-04794-8

Vancouver

Wells SA, Shapiro D, Borza T, Allen G, Hinshaw JL, Ziemlewicz TJ, et al. Percutaneous microwave ablation of cT1b renal cell carcinoma: safety and oncologic efficacy in a large, single-center elderly and comorbid cohort. Abdominal Radiology. 2025. doi:10.1007/s00261-024-04794-8

BibTeX
@article{Wells2025,
  author = {Wells, Shane A and Shapiro, Daniel and Borza, Tudor and Allen, Glenn and Hinshaw, J Louis and Ziemlewicz, Timothy J and Brace, Christopher L and Semerjian, Alice M and Abel, E Jason},
  title = {Percutaneous microwave ablation of cT1b renal cell carcinoma: safety and oncologic efficacy in a large, single-center elderly and comorbid cohort},
  journal = {Abdominal Radiology},
  year = {2025},
  doi = {10.1007/s00261-024-04794-8}
}
Kostenlos starten →